Johnson & Johnson (JNJ)

Over the past six months, Johnson & Johnson's stock price has significantly appreciated, closing at $237.79 on February 5, 2026, a 1.42% increase from the previous day. JNJ was up 16.11% over the past 30 days and 53.72% over the past 12 months, reaching new all-time highs. Valuation metrics are trading near their 10-year highs. In February 2026, promising results from the OMNY-AF study for treating atrial fibrillation were announced. In December 2025, acquisition strategies for 2026 were expected to be discussed at the JP Morgan Healthcare Conference.

Explicit information regarding the seasonality of demand for Johnson & Johnson's products and services is not clearly indicated in the provided search results. Reports mention overall demand trends rather than specific seasonal fluctuations. The company has focused on improving demand planning accuracy through enhanced statistical forecast models and increased market collaboration.

Johnson & Johnson (JNJ) is an American multinational corporation operating in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment focuses on therapeutic areas such as neuroscience, cardiovascular and metabolic health, immunology, oncology, pulmonary hypertension, and infectious diseases and vaccines, with key products treating conditions like psoriasis, multiple myeloma, and prostate cancer. The MedTech segment offers products in orthopedics, surgery, interventional solutions, and vision, including innovations in atrial fibrillation treatment. In 2023, JNJ spun off its consumer health division as Kenvue to focus on Innovative Medicine and MedTech.

Johnson & Johnson operates in over 60 countries with more than 275 subsidiaries, serving a worldwide market. In fiscal year 2024, the United States accounted for the largest share of revenue at $50.30 billion, followed by Europe at $20.21 billion, Asia-Pacific and Africa at $13.59 billion, and the Western Hemisphere (excluding the U.S.) at $4.71 billion.

Johnson & Johnson has maintained a strong brand reputation in the past year. The company was named a Fortune World's Most Admired Company for the 24th consecutive year in January 2026. In February 2026, JNJ reinforced its leadership in medical innovation by announcing new portfolio advancements in atrial fibrillation. In November 2024, Johnson & Johnson was recognized as a top five company by the Access to Medicine Index (ATMI) for its efforts to expand access to medicines and health technologies in lower- and middle-income countries. No significant negative events impacting Johnson & Johnson's brand reputation were prominently reported within the past year.

Johnson & Johnson has a substantial number of institutional owners and shareholders, with 5535 institutional owners holding 1,929,655,897 shares as of February 5, 2026. Major institutional shareholders include Vanguard Group Inc, BlackRock, Inc., and State Street Corp. Top individual shareholders include Alex Gorsky (Executive Chairman), Joaquin Duato (CEO), Paulus Stoffels, Ph.D. (former Chief Scientific Officer), Jennifer Taubert (pharmaceutical research division leader), and Joseph J. Wolk (CFO).